Mural Oncology plc (MURA)
NASDAQ: MURA · IEX Real-Time Price · USD
3.430
+0.010 (0.29%)
At close: Jul 19, 2024, 4:00 PM
3.480
+0.050 (1.46%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Mural Oncology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Mural Oncology stock have an average target of 14, with a low estimate of 13 and a high estimate of 15. The average target predicts an increase of 308.16% from the current stock price of 3.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mural Oncology stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|
| Strong Buy | 0 | 1 | 1 |
| Buy | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +337.32% | Jun 28, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $13 | Buy | Initiates | $13 | +279.01% | Apr 4, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-7.69
from -12.43
EPS Next Year
-4.02
from -7.69
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | n/a | n/a | 27.4M |
| Avg | n/a | n/a | 26.6M |
| Low | n/a | n/a | 25.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -7.92 | -4.14 | -2.36 |
| Avg | -7.69 | -4.02 | -2.30 |
| Low | -7.39 | -3.86 | -2.21 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.